Your browser doesn't support javascript.
loading
Intestinal Fatty Acid Binding Protein Levels in Pediatric Celiac Patients in Transition From Active Disease to Clinical and Serological Remission.
Hoofien, Assaf; Guz-Mark, Anat; Zevit, Noam; Tsadok Perets, Tsachi; Assa, Amit; Layfer, Olga; Matar, Manar; Nachmias-Friedler, Vered; Silbermintz, Ari; Shamir, Raanan.
Afiliação
  • Hoofien A; From the Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center, Petach Tikva, Israel.
  • Guz-Mark A; From the Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center, Petach Tikva, Israel.
  • Zevit N; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Tsadok Perets T; From the Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center, Petach Tikva, Israel.
  • Assa A; Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Layfer O; Gastroenterology Laboratory, Rabin Medical Center-Beilinson Hospital, Peath Tikva, Israel.
  • Matar M; Adelson School of Medicine, Ariel University, Ariel, Israel.
  • Nachmias-Friedler V; From the Institute of Gastroenterology, Nutrition and Liver Diseases, Schneider Children's Medical Center, Petach Tikva, Israel.
  • Silbermintz A; Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheba, Israel; 6Pediatric Gastroenterology and Nutrition Unit, Lady Davis Carmel Medical Center, Haifa, Israel.
  • Shamir R; Gastroenterology Laboratory, Rabin Medical Center-Beilinson Hospital, Peath Tikva, Israel.
JPGN Rep ; 2(2): e070, 2021 May.
Article em En | MEDLINE | ID: mdl-37207053
Celiac disease (CD) is increasingly diagnosed without endoscopy. As such, the need for accurate serological markers to aid in the diagnosis and follow-up of CD has increased. Intestinal fatty acid binding protein (I-FABP) is a cytosolic protein present in enterocytes, whose blood levels reflect mucosal damage in a reliable and quantifiable way. The aim of this study was to compare I-FABP levels in newly diagnosed patients with CD and to examine changes in levels following 6 months of gluten-free diet (GFD). Methods: A prospective observational case control study of pediatric patients diagnosed with CD, with measurements of tissue transglutaminase IgA (TTG-IgA) and I-FABP levels at diagnosis and after 6 months of gluten free diet were compared to a control group of nonceliac patients. Results: This study included 35 patients and 32 controls. The CD group had higher I-FABP levels at diagnosis compared with the control group (median 641.7 pg/mL versus 334 pg/mL; P < 0.05). I-FABP levels significantly differed between patients presenting with TTG-IgA level 3-10 times the upper limit of normal (ULN) compared with those presenting with values >10 times ULN (median 432.2 pg/mL versus 796.2 pg/mL; P < 0.05). Patients with CD had a significant decrease in median I-FABP levels after 6 months of GFD (median 268.2 pg/mL), paralleling a decrease in TTG-IgA and GFD adherence. Conclusions: I-FABP levels are increased in patients with CD at diagnosis compared with controls and decrease significantly while patients adhere to GFD.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Observational_studies Idioma: En Ano de publicação: 2021 Tipo de documento: Article